Clinical Trial Update: Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating navitoclax with vistusertib in relapsed small cell lung cancer and other solid tumors; the study is terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Small Cell Carcinoma
• Malignant Solid Neoplasm
• Small Cell Lung Cancer
• Stage Iiia Lung Small Cell Carcinoma
• Stage Iiib Lung Small Cell Carcinoma

Drugs mentioned

• Navitoclax (navitoclax)
• vistusertib (vistusertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-05-03